RETACRIT® (Epoetin alfa-epbx)

The FDA on May 15, 2018 approved RETACRIT® as a biosimilar to EPOGEN®/PROCRIT® (Epoetin alfa, Amgen Inc.), for the treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis, use of Zidovudine in patients with HIV infection and the effects of concomitant myelosuppressive chemotherapy. It is also approved for the reduction of allogeneic red blood cell transfusions in patients undergoing elective, noncardiac, nonvascular surgery. RETACRIT® is a product of Hospira Inc., a subsidiary of Pfizer Inc.